TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3140562

Group type: EXPERIMENTAL
Intervention: Flumazenil 1.0 mg i.v. at extubation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference group (thiopentone, alfentanil, nitrous oxide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIVA with midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study: 31937303

Group type: EXPERIMENTAL
Intervention: Increased urine output (UO) as a continuous variable
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Increased urine output (UO) as a quartile variable
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: UO/FI ratio ≤0.5 with increased UO/FI
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: UO/FI ratio >0.5
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: UO in subgroup with UO/FI ≤0.5
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: UO in subgroup with UO/FI >0.5
Number of subjects: 835
Study: 31675088

Group type: EXPERIMENTAL
Intervention: Family Connects (FC) program
Number of subjects: 936

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 936
Study: 28144131

Group type: EXPERIMENTAL
Intervention: Cranberry juice concentrate
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 227
Study: 25124456

Group type: EXPERIMENTAL
Intervention: Qigong/Tai Chi Easy (QG/TCE)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sham Qigong (SQG)
Number of subjects: 87
Study: 22893105

Group type: EXPERIMENTAL
Intervention: Finasteride (PCPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dutasteride (REDUCE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PCPT and REDUCE)
Number of subjects: 0
Study: 21205047

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) with dose adaptation based on saliva cotinine concentrations
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard care with nicotine patches and monthly dose decreases
Number of subjects: 310
Study: 18803492

Group type: EXPERIMENTAL
Intervention: Patient-selected music
Number of subjects: 80

Group type: COMPARATOR
Intervention: Silence (control group)
Number of subjects: 80
Study: 16540956

Group type: EXPERIMENTAL
Intervention: ivIGMA (1300 mL infused intravenously within a period of 72 hrs)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control (human albumin infused according to the same schedule as ivIGMA)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: ivIGMA
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control (human albumin)
Number of subjects: 211
Study: 12716966

Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0
Study: 10922313

Group type: COMPARATOR
Intervention: Arylane membrane
Number of subjects: 0
Study: 8807439

Group type: EXPERIMENTAL
Intervention: Pindolol 20 mg b.i.d. for 4 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg b.i.d. for 4 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 1391266

Group type: EXPERIMENTAL
Intervention: Natural porcine surfactant (Curosurf)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Nontreated control infants
Number of subjects: 13
Study: 3926732

Group type: EXPERIMENTAL
Intervention: Fast neutron therapy (mixed neutron-photon fractionated irradiation)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Photon irradiation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Fast neutron therapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 98
Study: 31560567

Group type: EXPERIMENTAL
Intervention: Conversation intervention (n=18)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Collaboration intervention (n=18)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waitlisted treatment-as-usual (control) (n=18)
Number of subjects: 54
Study: 31852650

Group type: EXPERIMENTAL
Intervention: Early physical therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapy of sepsis (Control)
Number of subjects: 60
Study: 28619235

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 742

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 742
Study: 25393889

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 150
Study: 24597974

Group type: EXPERIMENTAL
Intervention: Weight loss > 2 kg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Weight maintenance/gain
Number of subjects: 72
Study: 21924386

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) using an arterial occlusive cuff to one thigh for 5 min followed by deflation for 5 min for 4 cycles
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control condition (no IPC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 8
Study: 19442460

Group type: EXPERIMENTAL
Intervention: Monetary-based incentives for smoking-cessation and relapse prevention
Number of subjects: 316
Study: 17493777

Group type: EXPERIMENTAL
Intervention: Transvaginal estradiol (7.5 microg/24h)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No estradiol (Control)
Number of subjects: 115
Study: 15135009

Group type: EXPERIMENTAL
Intervention: Insulin (0.05 IU/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glucose (15%, 0.5 g/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (physiological saline 0.9%)
Number of subjects: 30
Study: 12389654

Group type: EXPERIMENTAL
Intervention: Urine screening for Chlamydia trachomatis and Neisseria gonorrhoeae by PCR
Number of subjects: 212

Group type: COMPARATOR
Intervention: Non-screening (control group)
Number of subjects: 212
Study: 9781472

Group type: EXPERIMENTAL
Intervention: Vitamin E (α-tocopherol) treatment (400-1600 IU/day)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Vitamin E (α-tocopherol) treatment
Number of subjects: 223
Study: 10147496

Group type: EXPERIMENTAL
Intervention: Two worksite health promotion sessions on responsible drinking
Number of subjects: 199
Study: 2908307

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Carvedilol 100 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Pindolol 15 mg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: All medications
Number of subjects: 205
Study: 16291892

Group type: EXPERIMENTAL
Intervention: Botulinum A toxin (100 U Allergan)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 30844842

Group type: EXPERIMENTAL
Intervention: 3.0 mm OCCIs
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 2.0 mm OCCIs
Number of subjects: 140

Group type: COMPARATOR
Intervention: 3.0 mm SCCI
Number of subjects: 140

Group type: COMPARATOR
Intervention: 2.0 mm SCCI
Number of subjects: 140
Study: 28768781

Group type: EXPERIMENTAL
Intervention: KneeAlign2 system (KA2 group)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Conventional intramedullary femoral guide (IM group)
Number of subjects: 241
Study: 26598177

Group type: EXPERIMENTAL
Intervention: Preoperative cognitive exercise (1 hour daily for 10 days before surgery)
Number of subjects: 264

Group type: COMPARATOR
Intervention: No preoperative intervention (control group)
Number of subjects: 264
Study: 23152480

Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control arm (standard ART without enfuvirtide)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Baseline RNA tropism
Number of subjects: 170
Study: 21784533

Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg/day for six weeks
Number of subjects: 93
Study: 19906348

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/d
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg/d
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 16823725

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 32
Study: 14638924

Group type: COMPARATOR
Intervention: High-flux dialysis
Number of subjects: 1846
Study: 10904025

Group type: EXPERIMENTAL
Intervention: Icatibant (10 mg IV) coadministered with perindoprilat (1.5 mg IV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Perindoprilat (1.5 mg IV)
Number of subjects: 12
Study: 9519139

Group type: EXPERIMENTAL
Intervention: SPF 17 broad spectrum sunscreen cream
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo base cream
Number of subjects: 431
Study: 8282427

Group type: EXPERIMENTAL
Intervention: Triclosan/Gantrez dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triclosan/pyrophosphate dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triclosan/zinc citrate dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control dentifrice (0.8% monofluorophosphate-silica)
Number of subjects: 0
Study: 3030387

Group type: EXPERIMENTAL
Intervention: Perindopril 16 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg and over
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31731111

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg by mouth daily for 90 days
Number of subjects: 120
Study: 28712686

Group type: EXPERIMENTAL
Intervention: Touch Surgery (TS) application
Number of subjects: 27

Group type: COMPARATOR
Intervention: Textbook
Number of subjects: 27
Study: 26589187

Group type: EXPERIMENTAL
Intervention: Maternal PTSD (high-risk group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Maternal PTSD (low-risk group)
Number of subjects: 68
Study: 25164452

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient fortified salt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 21067776

Group type: EXPERIMENTAL
Intervention: Cemented-EPS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cemented-CPS
Number of subjects: 20
Study: 20616365

Group type: EXPERIMENTAL
Intervention: Tetraplet-primed PCR (TP-PCR)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Short-range PCR (used in combination with TP-PCR)
Number of subjects: 213
Study: 18702776

Group type: EXPERIMENTAL
Intervention: Guided clinical reasoning
Number of subjects: 225

Group type: COMPARATOR
Intervention: Classic case discussions
Number of subjects: 225
Study: 15516352

Group type: COMPARATOR
Intervention: Ropivacaine 5 mg/ml in plain solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg/ml with glucose 50 mg/ml (hyperbaric solution)
Number of subjects: 40
Study: 12855328

Group type: EXPERIMENTAL
Intervention: Extended procedure (tip of the colonoscope remained in the rectum)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Control group (standard procedure)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Extended procedure
Number of subjects: 682
Study: 10596996

Group type: EXPERIMENTAL
Intervention: Hepcon group (360±80 IU/kg of heparin)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (300 IU/kg of heparin)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Hepcon group
Number of subjects: 57
Study: 8619357

Group type: EXPERIMENTAL
Intervention: iobitridol 300
Number of subjects: 68

Group type: COMPARATOR
Intervention: iopromide 300
Number of subjects: 68

Group type: COMPARATOR
Intervention: iopamidol 300
Number of subjects: 68
Study: 2027802

Group type: EXPERIMENTAL
Intervention: Subcutaneous long-acting epinephrine (Sus-Phrine), 0.005 ml per kg before albuterol aerosols
Number of subjects: 43

Group type: COMPARATOR
Intervention: Albuterol aerosols
Number of subjects: 43
Study: 7023861

Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.05 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of atropine and terbutaline sulfate (0.005 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Terbutaline sulfate (0.005 mg/kg)
Number of subjects: 12
Study: 30840136

Group type: EXPERIMENTAL
Intervention: 90 g h-1 glucose-fructose
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 100 g h-1 glucose-fructose
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 28025693

Group type: EXPERIMENTAL
Intervention: Laparoscopic herniorrhaphy (LH)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Open herniorrhaphy (OH)
Number of subjects: 41
Study: 26467136

Group type: EXPERIMENTAL
Intervention: Single Port Surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Classical Laparoscopic Cholecystectomy
Number of subjects: 30
Study: 23858719

Group type: EXPERIMENTAL
Intervention: Specific immune therapy (SIT)
Number of subjects: 40
Study: 22563485

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) applied to the occipital poles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control measure (overlay suppression)
Number of subjects: 0
Study: 20017325

Group type: EXPERIMENTAL
Intervention: Group psychological therapy for depression and anxiety during pregnancy (6 sessions, 1.5 hours each)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Group psychological therapy
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 800
Study: 17296230

Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery
Number of subjects: 400

Group type: COMPARATOR
Intervention: Manual small-incision cataract surgery (SICS)
Number of subjects: 400
Study: 15336297

Group type: EXPERIMENTAL
Intervention: Paroxetine (PAR) 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15279537

Group type: EXPERIMENTAL
Intervention: 7-session Iowa Strengthening Families Program (ISFP)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 5-session Preparing for the Drug Free Years Program (PDFY)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Minimal-contact control condition
Number of subjects: 33
Study: 10601133

Group type: EXPERIMENTAL
Intervention: SR49059 (300 mg oral dose)
Number of subjects: 24
Study: 7582278

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 750 micrograms twice daily
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1000 micrograms twice daily
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (both dosages)
Number of subjects: 96
Study: 1791718

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g, 1 tablet, 4 times a day for 20 days)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Venter (1 g, 1 tablet, 4 times a day for 20 days)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 82
Study: 6972165

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg zinc sulfate twice daily for a month)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 15
Study: 30718577

Group type: EXPERIMENTAL
Intervention: SnF2 and CPP-ACP nanocomplexes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 30070885

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CH) group with snack of high content of complex carbohydrates
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA) group with snack of high content of MUFA
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group with a minimum fast for three hours before the training session
Number of subjects: 19
Study: 26849684

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 25403296

Group type: EXPERIMENTAL
Intervention: Noofen (15‐20 mg/kg, 500‐700 mg per day, perorally in 2‐3 doses)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low doses of multivitamins (Control)
Number of subjects: 50
Study: 22081557

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 552

Group type: COMPARATOR
Intervention: Thiazolidinediones (TZDs)
Number of subjects: 552
Study: 20846424

Group type: EXPERIMENTAL
Intervention: Diet rich in various antioxidant-rich foods
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Kiwifruit diet (three kiwifruits/d added to the regular diet)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study: 17667984

Group type: EXPERIMENTAL
Intervention: Ramipril plus irbesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ramipril plus placebo
Number of subjects: 0
Study: 16194890

Group type: EXPERIMENTAL
Intervention: Post-treatment hemoglobin values
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Achievement of complete/partial remission
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Advanced stage (II-IV vs. I-II)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Pretreatment hemoglobin values
Number of subjects: 152
Study: 12200889

Group type: EXPERIMENTAL
Intervention: Erythromycin plus co-amoxiclav
Number of subjects: 4826

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 4826

Group type: COMPARATOR
Intervention: Co-amoxiclav plus erythromycin placebo
Number of subjects: 4826

Group type: COMPARATOR
Intervention: Erythromycin plus co-amoxiclav placebo
Number of subjects: 4826

Group type: COMPARATOR
Intervention: Co-amoxiclav placebo plus erythromycin placebo
Number of subjects: 4826
Study: 9500565

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 20
Study: 7608485

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30806017

Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 30014814

Group type: EXPERIMENTAL
Intervention: Height-for-age z-score (HAZ)
Number of subjects: 1649

Group type: EXPERIMENTAL
Intervention: Weight-for-age z-score (WAZ)
Number of subjects: 1649
Study: 26720250

Group type: EXPERIMENTAL
Intervention: IDegAsp[BIDSimple]
Number of subjects: 272

Group type: COMPARATOR
Intervention: IDegAsp[BIDStep-wise]
Number of subjects: 272
Study: 24716631

Group type: EXPERIMENTAL
Intervention: Brief Ageing Perceptions Questionnaire (B-APQ)
Number of subjects: 6718

Group type: COMPARATOR
Intervention: Original 32-item Ageing Perceptions Questionnaire (APQ)
Number of subjects: 6718
Study: 22658127

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody (BMS-936558) at a dose of 0.1 to 10.0 mg/kg every 2 weeks for up to 12 cycles.
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody (BMS-936558) at a dose of 0.1 to 10.0 mg/kg every 2 weeks.
Number of subjects: 296
Study: 20467629

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg taken four times a day for one week)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 17874878

Group type: EXPERIMENTAL
Intervention: Concurrent alcohol and tobacco treatment
Number of subjects: 0
Study: 15564947

Group type: EXPERIMENTAL
Intervention: Probenecid (500 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Quinidine (800 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11571099

Group type: EXPERIMENTAL
Intervention: High BDI scores in women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased clinic visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender effect on diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational and marital status
Number of subjects: 0
Study: 9456412

Group type: EXPERIMENTAL
Intervention: AcrySof lens with PMMA haptics
Number of subjects: 90

Group type: COMPARATOR
Intervention: PMMA lens
Number of subjects: 90

Group type: COMPARATOR
Intervention: Silicone lens
Number of subjects: 90
Study: 7946872

Group type: EXPERIMENTAL
Intervention: bupivacaine 100 mg and morphine 3 mg (group 3)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: bupivacaine 100 mg and morphine 1 mg (group 2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: bupivacaine 100 mg (group 1)
Number of subjects: 31
Study: 2899528

Group type: EXPERIMENTAL
Intervention: Individualized dietary counselling for 6 months
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Individualized dietary counselling for 12 months (6 months additional follow-up)
Number of subjects: 137
Study: 31999376

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously once every 6 months for 12 to 36 months
Number of subjects: 10036

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10036
Study: 30558577

Group type: EXPERIMENTAL
Intervention: Higher mid-arm muscle area (MAMA)
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Higher maternal weight
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Higher mid-upper arm circumference (MUAC)
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Higher MAMA
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Higher MUAC, BMI, and maternal weight
Number of subjects: 2369
Study: 28182503

Group type: EXPERIMENTAL
Intervention: Glucose Nasal Spray (GLUC NAS)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Caffeine Nasal Spray (CAF NAS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo Nasal Spray
Number of subjects: 11
Study: 26142584

Group type: EXPERIMENTAL
Intervention: Sildenafil dosage frequency ≤1 weekly
Number of subjects: 1699

Group type: EXPERIMENTAL
Intervention: Sildenafil dosage frequency 2-3 weekly
Number of subjects: 1699

Group type: EXPERIMENTAL
Intervention: Sildenafil dosage frequency 4-7 weekly
Number of subjects: 1699
Study: 23033239

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (mean weekly dose of 88,865 IU)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109